{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,29]],"date-time":"2025-10-29T03:54:52Z","timestamp":1761710092000,"version":"3.41.2"},"reference-count":26,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2024,2,26]],"date-time":"2024-02-26T00:00:00Z","timestamp":1708905600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Immunol."],"abstract":"<jats:p>Severe congenital neutropenia (SCN) is caused by germline mutations, most commonly in <jats:italic>ELANE<\/jats:italic>, impacting neutrophil maturation and leading to high risk of life-threatening infections. Most patients with <jats:italic>ELANE-<\/jats:italic>mutant SCN can achieve safe neutrophil counts with chronic Granulocyte-Colony Stimulating Factor (G-CSF). However, up to 10% of patients have neutropenia refractory to G-CSF and require allogeneic stem cell transplant. Traditional conditioning for these patients includes busulfan and cyclophosphamide which is associated with significant toxicities. We present five patients with SCN without myeloid malignancy transplanted using a reduced toxicity regimen of busulfan, fludarabine and thymoglobulin. 5 pediatric patients with SCN underwent matched sibling donor bone marrow transplant (MSD-BMT) between 2014-2022 on or per CHP14BT057 (NCT02928991), a prospective, single center trial testing elimination of cyclophosphamide from conditioning in pediatric patients with single lineage inherited BMF syndromes. All patients had MSDs and no evidence of MDS. Conditioning consisted of PK-adjusted busulfan, fludarabine, and thymoglobulin, with calcineurin inhibitor and mycophenolate mofetil GVHD prophylaxis. With median follow-up of 48.4 months, overall and event-free survival were 100%. There was no acute GVHD and one instance of chronic limited GVHD. Patients exhibited &amp;gt;95% donor myeloid chimerism at 5 years post-BMT. Two patients experienced CMV reactivation without end-organ disease, and no other viral reactivation or significant infections occurred. MSD-BMT with reduced toxicity myeloablation for SCN provides excellent outcomes while minimizing toxicity. These data suggest that busulfan, fludarabine, and ATG can be considered an efficacious, low-toxicity standard of care regimen for patients with SCN undergoing MSD-BMT.<\/jats:p>","DOI":"10.3389\/fimmu.2024.1369243","type":"journal-article","created":{"date-parts":[[2024,2,26]],"date-time":"2024-02-26T04:34:10Z","timestamp":1708922050000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":3,"title":["Reduced toxicity matched sibling bone marrow transplant results in excellent outcomes for severe congenital neutropenia"],"prefix":"10.3389","volume":"15","author":[{"given":"Joseph H.","family":"Oved","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nora M.","family":"Gibson","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kimberly","family":"Venella","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Caitlin W.","family":"Elgarten","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lisa","family":"Wray","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Julia T.","family":"Warren","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Timothy S.","family":"Olson","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1965","published-online":{"date-parts":[[2024,2,26]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.hoc.2012.11.003","article-title":"Epidemiology of congenital neutropenia","volume":"27","author":"Donadieu","year":"2013","journal-title":"Hematol Oncol Clin North Am"},{"key":"B2","doi-asserted-by":"publisher","DOI":"10.1182\/hematology.2022000392","article-title":"Genetics of severe congenital neutropenia as a gateway to personalized therapy","volume":"2022","author":"Donadieu","year":"2022","journal-title":"Hematol Am Soc Hematol Educ Program"},{"key":"B3","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaci.2023.02.016","article-title":"Homozygous DBF4 mutation as a cause of severe congenital neutropenia","volume":"152","author":"Willemsen","year":"2023","journal-title":"J Allergy Clin Immunol"},{"key":"B4","doi-asserted-by":"publisher","DOI":"10.1182\/blood.2022016783","article-title":"Human genetic defects in SRP19 and SRPRA cause severe congenital neutropenia with distinctive proteome changes","volume":"141","author":"Linder","year":"2023","journal-title":"Blood"},{"key":"B5","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2141.2007.06897.x","article-title":"Neutrophil elastase mutations and risk of leukaemia in severe congenital neutropenia","volume":"140","author":"Rosenberg","year":"2008","journal-title":"Br J Haematol"},{"key":"B6","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2006-08-019166","article-title":"Neutrophil elastase in cyclic and severe congenital neutropenia","volume":"109","author":"Horwitz","year":"2007","journal-title":"Blood"},{"key":"B7","doi-asserted-by":"publisher","DOI":"10.1038\/70544","article-title":"Mutations in ELA2, encoding neutrophil elastase, define a 21-day biological clock in cyclic haematopoiesis","volume":"23","author":"Horwitz","year":"1999","journal-title":"Nat Genet"},{"key":"B8","doi-asserted-by":"publisher","first-page":"17032","DOI":"10.1038\/nrdp.2017.32","article-title":"Severe congenital neutropenias","volume":"3","author":"Skokowa","year":"2017","journal-title":"Nat Rev Dis Primers"},{"key":"B9","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1097\/moh.0000000000000105","article-title":"The diversity of mutations and clinical outcomes for ELANE-associated neutropenia","volume":"22","author":"Makaryan","year":"2015","journal-title":"Curr Opin Hematol"},{"key":"B10","doi-asserted-by":"publisher","DOI":"10.1002\/humu.22308","article-title":"The spectrum of ELANE mutations and their implications in severe congenital and cyclic neutropenia","volume":"34","author":"Germeshausen","year":"2013","journal-title":"Hum Mutat"},{"key":"B11","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2005-11-4370","article-title":"The incidence of leukemia and mortality from sepsis in patients with severe congenital neutropenia receiving long-term G-CSF therapy","volume":"107","author":"Rosenberg","year":"2006","journal-title":"Blood"},{"key":"B12","doi-asserted-by":"publisher","DOI":"10.1056\/nejm198906153202402","article-title":"Effects of recombinant human granulocyte colony-stimulating factor on neutropenia in patients with congenital agranulocytosis","volume":"320","author":"Bonilla","year":"1989","journal-title":"N Engl J Med"},{"key":"B13","doi-asserted-by":"publisher","DOI":"10.3816\/SCT.2006.n.020","article-title":"The severe chronic neutropenia international registry: 10-year follow-up report","volume":"3","author":"Dale","year":"2006","journal-title":"Support Cancer Ther"},{"key":"B14","doi-asserted-by":"publisher","DOI":"10.1111\/j.1399-3046.2010.01386.x","article-title":"Indications for hematopoietic cell transplantation for children with severe congenital neutropenia","volume":"14","author":"Choi","year":"2010","journal-title":"Pediatr Transplant"},{"key":"B15","doi-asserted-by":"publisher","first-page":"492","DOI":"10.1182\/hematology.2021000284","article-title":"Diagnosis and therapeutic decision-making for the neutropenic patient","volume":"2021","author":"Connelly","year":"2021","journal-title":"Hematol Am Soc Hematol Educ Program"},{"key":"B16","doi-asserted-by":"publisher","first-page":"44","DOI":"10.1097\/MOH.0b013e32834da96e","article-title":"Hematopoietic stem cell transplantation for severe congenital neutropenia","volume":"19","author":"Connelly","year":"2012","journal-title":"Curr Opin Hematol"},{"key":"B17","doi-asserted-by":"publisher","DOI":"10.1038\/bmt.2015.238","article-title":"Busulfan fludarabine vs busulfan cyclophosphamide as a preparative regimen before allogeneic hematopoietic cell transplantation: systematic review and meta-analysis","volume":"51","author":"Ben-Barouch","year":"2016","journal-title":"Bone Marrow Transplant"},{"key":"B18","doi-asserted-by":"publisher","DOI":"10.1111\/petr.13078","article-title":"Successful second hematopoietic cell transplantation in severe congenital neutropenia","volume":"22","author":"Hashem","year":"2018","journal-title":"Pediatr Transplant"},{"key":"B19","doi-asserted-by":"publisher","DOI":"10.1002\/pbc.22836","article-title":"Hematopoietic stem cell transplantation in severe congenital neutropenia","volume":"56","author":"Carlsson","year":"2011","journal-title":"Pediatr Blood Cancer"},{"key":"B20","doi-asserted-by":"publisher","DOI":"10.1111\/j.1399-3046.2010.01319.x","article-title":"Hematopoietic stem cell transplantation in patients with severe congenital neutropenia: an analysis of 18 Japanese cases","volume":"14","author":"Oshima","year":"2010","journal-title":"Pediatr Transplant"},{"key":"B21","doi-asserted-by":"publisher","DOI":"10.1038\/s41409-020-0800-1","article-title":"HSCT may lower leukemia risk in ELANE neutropenia: a before-after study from the French Severe Congenital Neutropenia Registry","volume":"55","author":"Rotulo","year":"2020","journal-title":"Bone Marrow Transplant"},{"key":"B22","doi-asserted-by":"publisher","first-page":"45","DOI":"10.1038\/sj.bmt.1704718","article-title":"Hematopoietic stem cell transplantation in severe congenital neutropenia: experience of the French SCN register","volume":"35","author":"Ferry","year":"2005","journal-title":"Bone Marrow Transplant"},{"key":"B23","doi-asserted-by":"publisher","DOI":"10.1182\/blood.V95.4.1195.004k36_1195_1198","article-title":"Stem cell transplantation in patients with severe congenital neutropenia without evidence of leukemic transformation","volume":"95","author":"Zeidler","year":"2000","journal-title":"Blood"},{"key":"B24","doi-asserted-by":"publisher","DOI":"10.1016\/j.jtct.2021.09.018","article-title":"Impact of treosulfan exposure on early and long-term clinical outcomes in pediatric allogeneic hematopoietic stem cell transplantation recipients: A prospective multicenter study","volume":"28","author":"van der Stoep","year":"2022","journal-title":"Transplant Cell Ther"},{"key":"B25","doi-asserted-by":"publisher","DOI":"10.1111\/ejh.13828","article-title":"A retrospective study of treosulfan versus busulfan-based conditioning in pediatric patients","volume":"109","author":"Olivas-Maz\u00f3n","year":"2022","journal-title":"Eur J Haematol"},{"key":"B26","doi-asserted-by":"publisher","DOI":"10.1038\/s41409-021-01556-8","article-title":"Treosulfan-based conditioning regimen for allogeneic hematopoietic stem cell transplantation in children with non-malignant diseases","volume":"57","author":"Suh","year":"2022","journal-title":"Bone Marrow Transplant"}],"container-title":["Frontiers in Immunology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2024.1369243\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,2,26]],"date-time":"2024-02-26T04:34:14Z","timestamp":1708922054000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2024.1369243\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,2,26]]},"references-count":26,"alternative-id":["10.3389\/fimmu.2024.1369243"],"URL":"https:\/\/doi.org\/10.3389\/fimmu.2024.1369243","relation":{},"ISSN":["1664-3224"],"issn-type":[{"type":"electronic","value":"1664-3224"}],"subject":[],"published":{"date-parts":[[2024,2,26]]},"article-number":"1369243"}}